Skip to main content
main-content
Erschienen in: Der Gastroenterologe 3/2016

19.04.2016 | Diagnostik in der Gastroenterologie | CME

Nichtalkoholische Fettlebererkrankungen

verfasst von: MA Univ.-Prof. Dr. E. Roeb, A. Canbay

Erschienen in: Die Gastroenterologie | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Nichtalkoholische Fettlebererkrankungen (NAFLD) resultieren aus einem gestörten Gleichgewicht zwischen Fettakkumulation und Freisetzung von hepatozytären Fettreserven (De-novo-Lipogenese). Die individuelle Ernährung spielt in der Pathogenese von NAFLD eine herausragende Rolle. Es wurden sowohl ungünstige (z. B. konzentrierte Fruktosenahrung) als auch protektive Nahrungsmittel (Kaffee, mediterrane Kost) beschrieben. Adipositas, Diabetes mellitus Typ 2, Bewegungsmangel und Insulinresistenz gehören zu den Hauptrisikofaktoren der NAFLD. Entsprechend führt eine Gewichtsabnahme zu einer Verminderung des hepatischen Fettgehalts, zu einer Verbesserung der Steatohepatitis (NASH) und sogar zu einem Rückgang einer fettleberbedingten Fibrose. Trotz vielversprechender Studien (Obeticholsäure, Glitazone, Vitamin E u. a.) liegen bisher keine gesicherten Daten für eine pharmakologische Behandlung der NAFLD vor, sodass eine Änderung des Lifestyle (Ausdauertraining, langsame Gewichtsreduktion) die Basis der NAFLD-Therapie darstellt.
Literatur
2.
Zurück zum Zitat Roeb E, Steffen HM, Bantel H, Baumann U, Canbay A, Demir M, Drebber U, Geier A, Hampe J, Hellerbrand C, Pathil-Warth A, Schattenberg JM, Schramm C, Seitz HK, Stefan N, Tacke F, Tannapfel A, Lynen JP, Bojunga J (2015) S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 53:668–723 CrossRefPubMed Roeb E, Steffen HM, Bantel H, Baumann U, Canbay A, Demir M, Drebber U, Geier A, Hampe J, Hellerbrand C, Pathil-Warth A, Schattenberg JM, Schramm C, Seitz HK, Stefan N, Tacke F, Tannapfel A, Lynen JP, Bojunga J (2015) S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 53:668–723 CrossRefPubMed
3.
Zurück zum Zitat Marchesini G, Petta S, Dale Grave R (2015) Diet, Weight Loss, and Liver Health in NAFLD: Pathophysiology, Evidence and Practice. Hepatology : (in press) doi:10.1002/hep.28392 Marchesini G, Petta S, Dale Grave R (2015) Diet, Weight Loss, and Liver Health in NAFLD: Pathophysiology, Evidence and Practice. Hepatology : (in press) doi:10.1002/hep.28392
4.
Zurück zum Zitat Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M (2011) Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9:524–530 CrossRefPubMed Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M (2011) Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9:524–530 CrossRefPubMed
5.
Zurück zum Zitat Baffy G, Brunt EM, Caldwell SH (2012) Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 56:1384–1391 CrossRefPubMed Baffy G, Brunt EM, Caldwell SH (2012) Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 56:1384–1391 CrossRefPubMed
6.
Zurück zum Zitat Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B (2010) Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines. Pathologe 31:225–237 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B (2010) Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines. Pathologe 31:225–237
7.
Zurück zum Zitat Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ (2007) Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 47:239–244 CrossRefPubMed Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ (2007) Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 47:239–244 CrossRefPubMed
8.
Zurück zum Zitat Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Olbrisch ME, Posner MP (2000) Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation 69:1375–1379 CrossRefPubMed Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Olbrisch ME, Posner MP (2000) Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation 69:1375–1379 CrossRefPubMed
9.
Zurück zum Zitat Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285 CrossRefPubMed Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285 CrossRefPubMed
10.
Zurück zum Zitat Kemmer N, Neff GW, Franco E, Osman-Mohammed H, Leone J, Parkinson E, Cece E, Alsina A (2013) Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation. Transplantation 96:860–862 PubMed Kemmer N, Neff GW, Franco E, Osman-Mohammed H, Leone J, Parkinson E, Cece E, Alsina A (2013) Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation. Transplantation 96:860–862 PubMed
11.
Zurück zum Zitat Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128:2436–2443 CrossRefPubMed Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128:2436–2443 CrossRefPubMed
12.
Zurück zum Zitat Arslanow A, Stokes CS, Weber SN, Grünhage F, Lammert F, Krawczyk M (2015) The common PNPLA3 variant p.I148 M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP). Liver Int 36:418–426 (in press) doi:10.1111/liv.12937 CrossRefPubMed Arslanow A, Stokes CS, Weber SN, Grünhage F, Lammert F, Krawczyk M (2015) The common PNPLA3 variant p.I148 M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP). Liver Int 36:418–426 (in press) doi:10.1111/liv.12937 CrossRefPubMed
13.
Zurück zum Zitat Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H (2007) Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 92:3490–3497 CrossRefPubMed Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H (2007) Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 92:3490–3497 CrossRefPubMed
14.
Zurück zum Zitat Kälsch J, Bechmann LP, Heider D, Best J, Manka P, Kälsch H, Sowa JP, Moebus S, Slomiany U, Jöckel KH, Erbel R, Gerken G, Canbay A (2015) Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. Sci Rep 5:13058 CrossRefPubMedPubMedCentral Kälsch J, Bechmann LP, Heider D, Best J, Manka P, Kälsch H, Sowa JP, Moebus S, Slomiany U, Jöckel KH, Erbel R, Gerken G, Canbay A (2015) Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. Sci Rep 5:13058 CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kim D, Kim WR, Kim HJ, Therneau TM (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57:1357–1365 CrossRefPubMedPubMedCentral Kim D, Kim WR, Kim HJ, Therneau TM (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57:1357–1365 CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, Suh DJ, Kim KM, Bae MH, Lee JY, Lee SG, Yu ES (2010) Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 52:579–585 CrossRefPubMed Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, Suh DJ, Kim KM, Bae MH, Lee JY, Lee SG, Yu ES (2010) Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 52:579–585 CrossRefPubMed
17.
Zurück zum Zitat Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR (2009) Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 29:113–119 CrossRefPubMed Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR (2009) Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 29:113–119 CrossRefPubMed
18.
Zurück zum Zitat Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE (2006) In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44:27–33 CrossRefPubMed Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE (2006) In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44:27–33 CrossRefPubMed
20.
Zurück zum Zitat Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP (2007) The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854 CrossRefPubMed Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP (2007) The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854 CrossRefPubMed
21.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non- alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005–2023 CrossRefPubMed Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non- alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005–2023 CrossRefPubMed
22.
Zurück zum Zitat Thoma C, Day CP, Trenell MI (2012) Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 56:255–266 CrossRefPubMed Thoma C, Day CP, Trenell MI (2012) Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 56:255–266 CrossRefPubMed
23.
Zurück zum Zitat Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM (2010) Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51:1961–1971 CrossRefPubMedPubMedCentral Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM (2010) Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51:1961–1971 CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Te ML, Mallard S, Mann J (2013) Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ 346:e7492 Te ML, Mallard S, Mann J (2013) Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ 346:e7492
25.
Zurück zum Zitat Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C (2014) Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 20:16841–16857 CrossRefPubMedPubMedCentral Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C (2014) Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 20:16841–16857 CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C (2013) Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 11:1413–1421 (e1) CrossRefPubMed Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C (2013) Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 11:1413–1421 (e1) CrossRefPubMed
27.
Zurück zum Zitat Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA (2012) Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55:429–436 CrossRefPubMed Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA (2012) Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55:429–436 CrossRefPubMed
28.
Zurück zum Zitat Musso G, Cassader M, Rosina F, Gambino R (2012) Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55:885–904 CrossRefPubMed Musso G, Cassader M, Rosina F, Gambino R (2012) Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55:885–904 CrossRefPubMed
29.
Zurück zum Zitat Wree A, Schlattjan M, Bechmann LP, Claudel T, Sowa JP, Stojakovic T, Scharnagl H, Köfeler H, Baba HA, Gerken G, Feldstein AE, Trauner M, Canbay A (2014) Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metabolism 63:1542–1552 CrossRefPubMed Wree A, Schlattjan M, Bechmann LP, Claudel T, Sowa JP, Stojakovic T, Scharnagl H, Köfeler H, Baba HA, Gerken G, Feldstein AE, Trauner M, Canbay A (2014) Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metabolism 63:1542–1552 CrossRefPubMed
30.
Zurück zum Zitat Runkel N, Colombo-Benkmann M, Huttl TP, Tigges H, Mann O, Flade-Kuthe R, Shang E, Susewind M, Wolff S, Wunder R, Wirth A, Winckler K, Weimann A, de Zwaan M, Sauerland S (2011) Evidence-based German guidelines for surgery for obesity. Int J Colorectal Dis 26:397–404 CrossRefPubMed Runkel N, Colombo-Benkmann M, Huttl TP, Tigges H, Mann O, Flade-Kuthe R, Shang E, Susewind M, Wolff S, Wunder R, Wirth A, Winckler K, Weimann A, de Zwaan M, Sauerland S (2011) Evidence-based German guidelines for surgery for obesity. Int J Colorectal Dis 26:397–404 CrossRefPubMed
31.
Zurück zum Zitat Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP (2013) Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58:120–127 CrossRefPubMed Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP (2013) Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58:120–127 CrossRefPubMed
Metadaten
Titel
Nichtalkoholische Fettlebererkrankungen
verfasst von
MA Univ.-Prof. Dr. E. Roeb
A. Canbay
Publikationsdatum
19.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Gastroenterologie / Ausgabe 3/2016
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI
https://doi.org/10.1007/s11377-016-0063-y

Weitere Artikel der Ausgabe 3/2016

Der Gastroenterologe 3/2016 Zur Ausgabe

Schwerpunkt: Leben mit und nach Krebs

Die Rolle der Selbsthilfegruppen in der Onkologie

Einführung zum Thema

Leben mit und nach Krebs

Schwerpunkt: Leben mit und nach Krebs

Zur Problematisierung des Themas „cancer survivor“

Mitteilungen der Gastroenterologischen Arbeitsgemeinschaft Rheinland-Pfalz/Saarland (GARPS)

Mitteilungen der Gastroenterologischen Arbeitsgemeinschaft Rheinland-Pfalz/Saarland (GARPS)

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft basieren überwiegend auf den evidenzbasierten Leitlinien und den evidenzbasierten nationalen Versorgungsleitlinien der DDG und werden jährlich dem Stand der Wissenschaft angepasst.